PURPOSE: We have previously demonstrated associations between the urinary proteome profile and coronary artery disease (CAD) in cross-sectional studies. Here, we evaluate the potential of a urinary proteomic panel as a predictor of CAD in the hypertensive atherosclerotic cardiovascular disease (HACVD) substudy population of the Anglo-Scandinavian Cardiac Outcomes Trial study. EXPERIMENTAL DESIGN: Thirty-seven cases with primary CAD endpoint were matched for sex and age to controls who had not reached a CAD endpoint during the study. Spot urine samples were analyzed using CE coupled to Micro-TOF MS. A previously developed 238-marker CE-MS model for diagnosis of CAD (CAD238 ) was assessed for its predictive potential. RESULTS: Sixty urine samples (32 cases; 28 controls; 88% male, mean age 64 ± 5 years) were analyzed. There was a trend toward healthier values in controls for the CAD model classifier (-0.432 ± 0.326 versus -0.587 ± 0.297, p = 0.170), and the CAD model showed statistical significance on Kaplan-Meier survival analysis p = 0.021. We found 190 individual markers out of 1501 urinary peptides that separated cases and controls (AUC >0.6). Of these, 25 peptides were also components of CAD238 . CONCLUSION AND CLINICAL RELEVANCE: A urinary proteome panel originally developed in a cross-sectional study predicts CAD endpoints independent of age and sex in a well-controlled prospective study.
PURPOSE: We have previously demonstrated associations between the urinary proteome profile and coronary artery disease (CAD) in cross-sectional studies. Here, we evaluate the potential of a urinary proteomic panel as a predictor of CAD in the hypertensive atherosclerotic cardiovascular disease (HACVD) substudy population of the Anglo-Scandinavian Cardiac Outcomes Trial study. EXPERIMENTAL DESIGN: Thirty-seven cases with primary CAD endpoint were matched for sex and age to controls who had not reached a CAD endpoint during the study. Spot urine samples were analyzed using CE coupled to Micro-TOF MS. A previously developed 238-marker CE-MS model for diagnosis of CAD (CAD238 ) was assessed for its predictive potential. RESULTS: Sixty urine samples (32 cases; 28 controls; 88% male, mean age 64 ± 5 years) were analyzed. There was a trend toward healthier values in controls for the CAD model classifier (-0.432 ± 0.326 versus -0.587 ± 0.297, p = 0.170), and the CAD model showed statistical significance on Kaplan-Meier survival analysis p = 0.021. We found 190 individual markers out of 1501 urinary peptides that separated cases and controls (AUC >0.6). Of these, 25 peptides were also components of CAD238 . CONCLUSION AND CLINICAL RELEVANCE: A urinary proteome panel originally developed in a cross-sectional study predicts CAD endpoints independent of age and sex in a well-controlled prospective study.
Authors: Dongmei Wei; Jesus D Melgarejo; Lutgarde Thijs; Xander Temmerman; Thomas Vanassche; Lucas Van Aelst; Stefan Janssens; Jan A Staessen; Peter Verhamme; Zhen-Yu Zhang Journal: J Am Heart Assoc Date: 2022-04-12 Impact factor: 6.106
Authors: Nay M Htun; Dianna J Magliano; Zhen-Yu Zhang; Jasmine Lyons; Thibault Petit; Esther Nkuipou-Kenfack; Adela Ramirez-Torres; Constantin von Zur Muhlen; David Maahs; Joost P Schanstra; Claudia Pontillo; Martin Pejchinovski; Janet K Snell-Bergeon; Christian Delles; Harald Mischak; Jan A Staessen; Jonathan E Shaw; Thomas Koeck; Karlheinz Peter Journal: PLoS One Date: 2017-03-08 Impact factor: 3.240
Authors: Gemma E Currie; Bernt Johan von Scholten; Sheon Mary; Jose-Luis Flores Guerrero; Morten Lindhardt; Henrik Reinhard; Peter K Jacobsen; William Mullen; Hans-Henrik Parving; Harald Mischak; Peter Rossing; Christian Delles Journal: Cardiovasc Diabetol Date: 2018-04-06 Impact factor: 9.951